Skip to main content

COVID-19 Update

CSL continues to provide medicines to patients around the world.


Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new ways to specifically help those affected by COVID-19. In addition, we have taken measures to support the health and well-being of our people. We continue to closely monitor the outbreak to minimize business impact. (CSL is the parent company of CSL Behring and Seqirus)

Our Efforts:
We have joined with other leading plasma companies to form the CoVIg-19 Plasma Alliance, an unprecedented industry collaboration with a goal of developing and delivering an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19. A Phase III trial is under way. 

We’re also partnered with the Coalition for Epidemic Preparedness (CEPI) to fund the development and manufacture of University of Queensland’s (UQ) “molecular clamp” enabled vaccine. We’ve committed to supply 51 million doses of UQ vaccine to the Australian government, should clinical trials be successful. In addition, CSL and AstraZeneca have agreed for CSL to manufacture approximately 30 million doses of the Oxford University vaccine candidate AZD1222, for supply to Australia.

These are just some of our many efforts to combat the global pandemic. To see what else we are doing, please see our Fact Sheet.

Our People:

We have taken numerous steps to help ensure the health and safety of our workforce. This includes restricting international travel through the end of 2020, postponing large group meetings, and encouraging employees to leverage various communication technologies to minimize business disruption.

Our Patients & Products:

  • CSL continues to provide an uninterrupted supply of our medicines around the world. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.

  • We have ongoing clinical trials at investigational sites worldwide and remain in close contact with researchers who are involved in this important work to evaluate promising new medicines, discussing the best ways to manage patient visits and follow-up appointments.

  • We are supporting the University of Queensland (AUS) in its effort to develop a COVID-19 vaccine by providing technical expertise. As part of this partnership, we have made a donation of our company’s proprietary adjuvant technology, MF59®, to the university’s pre-clinical development program.

Our Donors:

Our plasma collection network is operational. Our plasma centers are committed to the highest standards of quality and safety for our employees and donors.